O. Tohyama

Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor

D. Ito, K. Sawada, K. Miyazaki, 2011, International journal of molecular medicine.

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Y. Oda, K. Aoshima, Taisuke Uehara, 2014, Cancer science.

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Masao Iwata, Osamu Tohyama, Takayuki Kimura, 2014, Journal of thyroid research.

E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models

T. Nakagawa, Keiko Takahashi, T. Matsushima, 2010, Cancer science.

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Z. Dezső, Yuji Yamamoto, Keiko Takahashi, 2014, Vascular cell.

Wif1 and Ifitm3 gene expression preferentially altered in the colon mucosa of benzo[a]pyrene pre-treated mice following exposure to dextran sulfate sodium.

S. Asakura, N. Toritsuka, A. Hakura, 2015, Chemico-biological interactions.

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus

K. Okamoto, Y. Funahashi, J. Matsui, 2017, Cancer science.

Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti-angiogenesis activity in a preclinical cancer model

T. Nakagawa, Y. Funahashi, T. Matsushima, 2015, Cancer science.